Dublin-listed pharmaceutical services company Open Orphan said it is planning for a possible spin-out of some of its non-core development intellectual property assets. The company said it believed the assets in question...

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that it is...

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary...

The UK’s COVID-19 human challenge study has reached its first milestone after administering virus to three volunteers in a controlled clinical setting The first participants recruited to the landmark trial have now completed...

Speculation is mounting that Open Orphan, a clinical trial company headed by Irish dealmaker Cathal Friel, will move to spin off its stake in vaccine developer Imutex via a Nasdaq...

Dublin-listed pharmaceutical services company Open Orphan’s subsidiary Hvivo has won a contract worth €7.5 million to run a human viral challenge study. Open Orphan, a European-focused, rare and orphan drug consulting services...

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary...

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced an update in the...

Britain is the first country in the world to launch the Human Challenge study, which will require up to 90 volunteers aged 18 to 30 years being exposed to coronavirus...

Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appointments. Lisa Runco, Ph.D., has been...